Latest Lead News

Chimeric Therapeutics has dosed the first three patients in its Phase 1/2 CHM CDH17 CAR-T trial targeting gastrointestinal cancers, alongside advancing its AML and NK cell therapy programs. The company also secured $5 million in funding and appointed Dr Rebecca McQualter as CEO.

Vectus Biosystems reports completion of Phase Ib trials for its lead drug VB0004 and a robust cash position bolstered by a significant R&D tax refund, setting the stage for licensing discussions.

Dotz Nano Limited has landed its first commercial order for DotzShield in the U.S. and made significant strides in carbon capture technology development, including a new sorbent for Direct Air Capture and a strategic collaboration with Bar-Ilan University.

Arovella Therapeutics has bolstered its financial position with a $20 million placement, fully funding the Phase 1 clinical trial of its lead CAR-iNKT therapy, ALA-101, targeting CD19-positive blood cancers. The company also established a Clinical Advisory Board and anticipates key regulatory and clinical milestones in 2025.

Marquee Resources delivers a robust December quarter update, spotlighting strong drilling results at Redlings Rare Earth Project and a maiden Inferred Mineral Resource Estimate, while advancing exploration across multiple strategic projects.

Andromeda Metals has made significant strides in advancing its Great White Project, progressing funding efforts for Stage 1A+ and securing key operational milestones. The company also bolstered its leadership with new board appointments and received a substantial tax refund, positioning it for a critical investment decision.

Lincoln Minerals reports compelling Pre-Feasibility Study results for its Kookaburra Graphite Project, alongside strategic cost reductions and exploration progress in uranium and base metals on South Australia's Eyre Peninsula.

Peninsula Energy has resumed uranium production at its flagship Lance Projects in Wyoming after a five-year pause, marking a pivotal step towards becoming a fully independent uranium producer. The company also announced key executive appointments and progress on plant construction despite some cost overruns and operational challenges.

Accelerate Resources has successfully raised $1.35 million to accelerate exploration at its newly acquired Kanowna East Gold Project, marking a strategic push into the prolific Kalgoorlie gold region.

Emperor Energy has secured $3 million through a share placement to fund the Judith-2 Well development, appointing a suite of technical consultants to accelerate progress in the Gippsland Basin. The company’s strategic moves position it to unlock significant gas resources critical for South-Eastern Australia’s energy supply.

Opthea Limited reports steady progress in its Phase 3 trials for sozinibercept, a novel treatment for wet AMD, supported by a strong cash position and a recent R&D tax incentive.

Nova Eye Medical Limited is raising A$6.6 million to strengthen its financial position following resolved supply chain disruptions, while reporting strong sales growth and nearing profitability in its glaucoma division.